As shown in Fig. 3D, compared with the non-EGFR-TKI treatment group, adjuvant EGFR-TKI treatment could significantly prolong the OS in EGFR-mutant patients with stage III NSCLC, with a HR of 0.35 (95% CI, 0.23–0.54, P < 0.001). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.